New combo therapy aims to boost survival in severe alcoholic hepatitis

NCT ID NCT06956482

Recruiting now Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding N-acetylcysteine or extending prednisolone treatment beyond the standard 30 days can improve outcomes for people with severe alcoholic hepatitis. About 477 participants will be enrolled. The goal is to see if these strategies increase the number of patients alive with better liver function at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-acetylcysteine and prednisolone
What this could lead to: If successful, this could provide a new treatment strategy to reduce deaths and liver damage in severe alcoholic hepatitis.
What could go wrong: This is a phase 3 trial, but previous similar strategies have failed. The benefit may be modest, and side effects from steroids or NAC are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOLIC HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcoholic hepatitis Hepatic Insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOLIC HEPATITIS

Contacts and locations

Locations

CHU de Lille, Hôpital Huriez
RECRUITING

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.